FAM86C1P

Across TCGA pan-cancer cohorts, FAM86C1P RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated FAM86C1P data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM86C1P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated FAM86C1P expression acts as an unfavorable survival marker, although some lineages such as OV and BRCA show a favorable association.

LIHC, OV, and LGG are the cancer types where FAM86C1P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.710	0.834	<.001	97	view →
OV	DFS	Quartile	All	0.596	0.475	.010	62	view →
LGG	DFS	Median	All	0.651	0.825	<.001	51	view →
BLCA	DFS	Tertile	All	0.189	0.522	.003	49	view →
BRCA	OS	Tertile	IV	0.926	0.253	.001	46	view →
ESCA	DFS	Tertile	All	0.886	0.324	.009	45	view →
UVM	DFS	Quartile	All	1.000	0.239	.006	31	view →
LUAD	OS	Quartile	All	0.759	0.937	.001	31	view →
PAAD	DFS	Median	All	0.375	0.622	.002	26	view →
THYM	DFS	Median	All	1.000	0.810	.001	26	view →
LUSC	DFS	Tertile	II,III,IV	0.907	0.590	.007	21	view →
THCA	DFS	Median	III,IV	0.808	0.602	.010	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

FAM86C1P–LIHC (OS)

Open the LIHC breakdown →